Goenka Luxitaa, George Melvin, Singh Vishakha, Jena Amrita, Seshadri Deepika, Karunakaran Vasanth, Elumalai Dhandapani Vellala, Rani Jamuna, Kaliappan Ilango
Department of Clinical Pharmacology, SRM MCH & RC, Kattankulathur, Chennai, Tamil Nadu, India.
Department of Clinical Pharmacology, SRM MCH & RC, Kattankulathur, Chennai, Tamil Nadu, 603203, India.
Ther Adv Cardiovasc Dis. 2017 Oct;11(10):261-270. doi: 10.1177/1753944717723311. Epub 2017 Aug 10.
Coronary artery disease (CAD) is one of the leading causes of mortality and morbidity worldwide. We thereby sought to investigate whether the biomarkers, angiopoietin-like 4 (ANGPTL-4) and galectin-3, reflect the severity of CAD.
Patients were screened based on inclusion/exclusion criteria and written informed consent was obtained from the patients. Serum ANGPTL-4 and galectin-3 was quantified using enzyme-linked immunosorbent assay (ELISA) and correlated with the Global Registry of Acute Coronary Events (GRACE) and GENSINI score using Spearman's rank correlation coefficient and multivariate analysis.
A total of 226 patients consisting of ST-segment elevation myocardial infarction (STEMI), non-STEMI/unstable angina (USA), chronic stable angina (CSA) and normal controls (NCs) participated in the study. ANGPTL-4 and galectin-3 were significantly higher in CAD than the NC group. ANGPTL-4 showed significant negative correlation with GRACE score in acute coronary syndrome (ACS) ( r = -0.211, p = 0.03) patients. ANGPTL-4 showed significant positive correlation with serum creatinine ( r = 0.304, p = 0.056) and body mass index (BMI) ( r = 0.424, p = 0.009) in CSA patients. A modest positive correlation was observed between the serum galectin-3 levels and GRACE score ( r = 0.187, p = 0.055) in ACS patients. However, on multivariate analysis the positive correlation relationship between ANGPTL-4 and galectin-3 with the severity of CAD was not sustained.
In conclusion, ANGPTL-4 and galectin-3 do not appear to have a promising role for assessing the severity of CAD. Nevertheless these biomarkers do warrant further exploration in improving the management of CAD.
冠状动脉疾病（CAD）是全球死亡率和发病率的主要原因之一。因此，我们试图研究生物标志物血管生成素样4（ANGPTL-4）和半乳糖凝集素-3是否能反映CAD的严重程度。
根据纳入/排除标准对患者进行筛选，并获得患者的书面知情同意书。采用酶联免疫吸附测定（ELISA）对血清ANGPTL-4和半乳糖凝集素-3进行定量，并使用Spearman等级相关系数和多变量分析将其与急性冠状动脉事件全球注册（GRACE）和GENSINI评分相关联。
共有226名患者参与了该研究，包括ST段抬高型心肌梗死（STEMI）、非STEMI/不稳定型心绞痛（USA）、慢性稳定型心绞痛（CSA）和正常对照（NC）。CAD患者的ANGPTL-4和半乳糖凝集素-3显著高于NC组。在急性冠状动脉综合征（ACS）患者中，ANGPTL-4与GRACE评分呈显著负相关（r = -0.211，p = 0.03）。在CSA患者中，ANGPTL-4与血清肌酐（r = 0.304，p = 0.056）和体重指数（BMI）（r = 0.424，p = 0.009）呈显著正相关。在ACS患者中，血清半乳糖凝集素-3水平与GRACE评分之间观察到适度正相关（r = 0.187，p = 0.055）。然而，多变量分析显示ANGPTL-4和半乳糖凝集素-3与CAD严重程度之间的正相关关系并不持续。
总之，ANGPTL-4和半乳糖凝集素-3在评估CAD严重程度方面似乎没有显著作用。然而，这些生物标志物在改善CAD管理方面确实值得进一步探索。
